

## Erratum

# Occupational exposure to asbestos and mortality among asbestos removal workers: a Poisson regression analysis

---

**G Frost, A-H Harding, A Darnton, D McElvenny and D Morgan**

---

*British Journal of Cancer* (2008) **99**, 1954–1957. doi:10.1038/sj.bjc.6604798 www.bjcancer.com  
© 2008 Cancer Research UK

**Correction to:** *British Journal of Cancer* (2008) **99**, 822–829, doi:10.1038/sj.bjc.6604564

Owing to an error during typesetting, there were some mistakes introduced into the layouts of Tables 2 and 3 in the above paper when first published in the *British Journal of Cancer* in September 2008. The presentation of the tables as such may have

led to misinterpretation of data; indeed, some data were presented incorrectly in Table 3.

The tables are now reproduced, as the author intended, on the following pages.

The publishers would like to apologise for these errors.

**Table 2** Standardised mortality ratios (SMR) for all asbestos removal workers in the survey and for those included in the analysis (1971–2005)

Cause of death	All removal workers		Analysed workers	
	Deaths	SMR (95% CI)	Deaths	SMR (95% CI)
All causes	3165	122.9** (118.7–127.3)	985	111.3** (104.4–118.4)
All MN	1274	173.1** (163.7–182.9)	384	169.2** (152.7–187.0)
MN of lip, oral cavity and pharynx	19	94.0 (56.6–146.9)	6	83.7 (30.7–182.2)
MN of oesophagus	42	88.2 (63.5–119.2)	16	104.2 (59.6–169.2)
MN of stomach	49	133.7 (98.9–176.8)	18	176.4* (104.5–278.8)
MN of colon	62	127.9 (98.1–163.9)	17	119.2 (69.4–190.9)
MN of rectum	43	169.0** (122.3–227.6)	15	207.1* (115.9–341.5)
MN of liver (primary)	20	126.6 (77.3–195.5)	9	167.8 (76.7–318.6)
MN of larynx	17	212.3** (123.6–339.8)	8	322.9** (139.4–636.1)
MN trachea, bronchus and lung	393	200.5** (181.2–221.4)	115	215.6** (178.0–258.7)
MN of peritoneum	38	4568.9** (3233.2–6271.2)	12	4367.8** (2257.0–7629.8)
MN of pleura	35	1149.3** (800.5–1598.4)	10	1332.8** (639.1–2451.1)
Mesothelioma <sup>a</sup>	69	808.2** (628.8–1022.8)	23	808.2** (512.3–1212.7)
MN of ovary	0	— (0.0–533.0)	0	— (0.0–7092.9)
MN of kidney	29	160.1* (107.2–229.9)	13	229.0* (121.9–391.6)
MN of bladder	18	94.2 (55.8–148.8)	3	61.6 (12.7–180.2)
MN of lymphatic and haematopoietic tissue	80	103.9 (82.4–129.3)	24	86.2 (55.2–128.2)
Circulatory disease	981	114.0** (107.0–121.4)	258	102.0 (89.9–115.2)
Ischaemic heart disease	665	113.3** (104.9–122.3)	171	102.4 (87.7–119.0)
Cerebrovascular disease	147	125.0* (105.6–146.9)	41	118.3 (84.9–160.5)
Respiratory disease	222	128.0** (111.7–146.0)	44	88.8 (64.5–119.2)
Asbestosis <sup>b</sup>	22	5753.4** (3605.6–8710.7)	3	3849.6** (794.3–11249.8)

CI = confidence interval. \*Significant at  $P \leq 0.05$ ; \*\*significant at  $P \leq 0.01$ . <sup>a</sup>ICD-10, after 2001. <sup>b</sup>Asbestosis determined by underlying cause of death.



Table 3 (Continued)

	Mesothelioma <sup>b</sup>			Circulatory disease			Ischaemic heart disease		
	Cases	RR <sup>a</sup> (95% CI)	LR test (d.f.)	Cases	RR <sup>a</sup> (95% CI)	LR test (d.f.)	Cases	RR <sup>a</sup> (95% CI)	LR test (d.f.)
Age at first exposure (years)			22.12 (1)**			12.38 (4)*			12.71 (4)*
< 20 <sup>c</sup>	14	1.0		44	1.0		33	1.0	
20–	9	0.1 (0.1–0.3)**		41	0.8 (0.5–1.2)		19	0.5 (0.3–0.9)*	
30–	—			51	1.0 (0.7–1.6)		34	0.9 (0.6–1.5)	
40–	—			78	1.5 (1.0–2.2)*		54	1.3 (0.9–2.1)	
50+	—			44	0.9 (0.6–1.4)		31	0.9 (0.5–1.5)	
Length of time in the survey			8.23 (1)**			0.00 (1)			0.60 (1)
Short term <sup>c</sup>	3	1.0		102	1.0		72	1.0	
Long term	20	4.5 (1.3–16.0)*		156	1.0 (0.8–1.3)		99	0.9 (0.6–1.2)	
Length of exposure (years)			18.59 (1)**			7.19 (4)			10.39 (4)*
< 10 <sup>c</sup>	—			141	1.0		92	1.0	
10–	—			48	1.0 (0.7–1.4)		36	1.2 (0.8–1.7)	
20–	9 <sup>d</sup>	1.0		27	0.8 (0.5–1.2)		14	0.6 (0.3–1.0)	
30–	14	7.3 (2.5–21.6)**		20	0.6 (0.4–0.9)*		13	0.6 (0.3–1.0)*	
40+	—			22	0.9 (0.6–1.5)		16	1.1 (0.6–1.9)	
Time of first exposure			13.15 (1)**			0.46 (1)			0.84 (1)
Pre-ALR <sup>e</sup>	19	1.0		123	1.0		81	1.0	
Post-ALR	4	—		135	1.1 (0.8–1.4)		90	1.2 (0.8–1.6)	
	Cerebrovascular disease			Respiratory disease					
	Cases	RR <sup>a</sup> (95% CI)	LR test (d.f.)	Cases	RR <sup>a</sup> (95% CI)	LR test (d.f.)			
Main stripping method			0.62 (2)			2.46 (2)			
Wet <sup>c</sup>	18	1.0		23	1.0				
Dry	14	0.8 (0.4–1.5)		13	0.6 (0.3–1.2)				
Both	2	—		4	—				
Main respirator type			7.12 (6)			4.02 (6)			
Positive pressure mask <sup>c</sup>	31	1.0		33	1.0				
Airstream helmet	0	—		0	—				
Full face unpowered mask	4	—		4	—				
Half face mask	0	—		0	—				
Minimal	1	—		1	—				
None	0	—		0	—				
Mixed	0	—		3	—				
Weekly hours spent stripping			0.68 (2)			3.46 (3)			
< 10 <sup>c</sup>	21	1.0		21	1.0				
10–	10	1.4 (0.6–2.9)		8	1.1 (0.5–2.5)				
30–	10	1.2 (0.6–2.7)		7	2.0 (0.8–4.6)				
40+	—			8	1.9 (0.9–4.1)				
Smoking status			5.96 (2)			14.18 (2)**			
Never smokers <sup>c</sup>	12	1.0		2	1.0				
Current smokers	22	0.9 (0.4–1.8)		30	7.4 (1.8–30.6)**				
Former smokers	6	0.3 (0.1–0.9)*		11	3.8 (0.8–17.2)				
Age at first exposure (years)			3.04 (4)			4.35 (3)			
< 20 <sup>c</sup>	6	1.0		6	1.0				
20–	8	1.1 (0.4–3.2)		12	1.7 (0.7–4.8)				
30–	8	1.5 (0.5–4.7)		12	2.1 (0.8–5.3)				
40–	12	2.2 (0.8–6.6)		14	1.0 (0.4–2.6)				
50+	7	1.3 (0.4–4.4)		—					
Length of time in the survey			0.45 (1)			0.46 (1)			
Short term <sup>c</sup>	15	1.0		20	1.0				
Long term	26	1.2 (0.7–2.3)		24	0.8 (0.5–1.5)				
Length of exposure (years)			0.94 (2)			7.14 (3)			
< 10 <sup>c</sup>	24	1.0		25	1.0				
10–	6	0.8 (0.3–1.9)		6	0.4 (0.2–1.1)				
20–	11	0.7 (0.3–1.5)		—					
30–	—			6	1.1 (0.4–2.7)				
40+	—			7	1.9 (0.8–4.4)				
Time of first exposure			1.16 (1)			0.01 (1)			
Pre-ALR <sup>e</sup>	18	1.0		22	1.0				
Post-ALR	23	1.4 (0.7–2.8)		22	1.0 (0.5–1.8)				

CI = confidence interval; d.f. = degrees of freedom; LR test = likelihood ratio test of goodness-of-fit. \*significant at  $P \leq 0.05$ ; \*\*significant at  $P \leq 0.01$ . <sup>a</sup>Relative risk adjusted with Poisson regression for age, calendar period and sex. <sup>b</sup>ICD-10, after 2001. <sup>c</sup>Reference category. <sup>d</sup>Categories: < 30, 30+.